Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Fineline Cube Jan 27, 2026
Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Fineline Cube Jan 27, 2026
Company Deals

Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform

Fineline Cube Jan 26, 2026
Company Deals

GenEditBio Partners with uBriGene on LNP Ex Vivo Tech for Cell Therapy Manufacturing

Fineline Cube Jan 26, 2026
Company Deals

Merck Abandons $32 Billion Revolution Medicines Acquisition Over Price Dispute

Fineline Cube Jan 26, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Drug

Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency

Fineline Cube Jan 27, 2026
Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Fineline Cube Jan 26, 2026
Company Deals

CARsgen and Huadong Medicine Partner to Commercialize BCMA CAR-T Product CT053 in China

Fineline Cube Jan 17, 2023

China-based CARsgen Therapeutics Holdings Limited (HKG: 2171), a leading developer of innovative CAR T-cell therapies,...

Company Deals

Tongshu Gene Partners with LC Gene to Distribute Gene Mutation Detection Kit in China

Fineline Cube Jan 17, 2023

China-based gene testing service providers Tongshu Gene and LC Gene Diagnostics (Hangzhou) Co., Ltd. have...

Company Drug

3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer

Fineline Cube Jan 16, 2023

China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...

Company Drug

Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11

Fineline Cube Jan 16, 2023

China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...

Company Deals

Base Therapeutics Secures Series A1 Funding to Advance Gene Editing Pipelines

Fineline Cube Jan 16, 2023

Base Therapeutics, a Guangdong-based firm specializing in base editing and prime editing technologies, has reportedly...

Company Deals

ConceMed Raises Pre-Series A Funding to Expand Digestive Endoscope Pipeline

Fineline Cube Jan 16, 2023

ConceMed, a Guangdong-based maker of digestive soft electronic endoscopes, has reportedly raised “tens of millions”...

Company Drug

Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder

Fineline Cube Jan 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food...

Company

WuXi Biologics CEO Outlines Growth Amid Global Challenges at J.P. Morgan Conference

Fineline Cube Jan 16, 2023

China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where...

Company Drug

Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA

Fineline Cube Jan 16, 2023

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...

Company Deals

ReLive Biotechnologies Acquires Co.Don AG, Secures USD 36 Million for Expansion

Fineline Cube Jan 16, 2023

Tissue engineering and regenerative medicine start-up ReLive Biotechnologies Ltd has announced the full acquisition of...

Company Drug

Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication

Fineline Cube Jan 16, 2023

China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical...

Company Drug

Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023

Fineline Cube Jan 16, 2023

China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization...

Company Drug

Amoytop’s AK0706 Receives Clinical Trial Approval for Hepatitis B Treatment

Fineline Cube Jan 16, 2023

Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...

Company Deals

JHM Biopharma Raises RMB100 Million to Expand Protein Drug Pipeline

Fineline Cube Jan 16, 2023

Hangzhou-based protein drug developer JHM Biopharma has reportedly secured close to RMB100 million (USD14.9 million)...

Company Drug

Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE

Fineline Cube Jan 16, 2023

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing...

Company Deals

Meheco’s Genertec Partners with AstraZeneca for COVID-19 Antibody Evusheld in China

Fineline Cube Jan 16, 2023

China Meheco Group Co., Ltd (SHA: 600056) announced that its subsidiary Genertec Meheco has entered...

Company Drug

Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038

Fineline Cube Jan 16, 2023

Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...

Company Deals

Eyougene Raises Hundreds of Millions in Series B Funding for Expansion

Fineline Cube Jan 13, 2023

Eyougene Co., Ltd, a digital Contract Development and Manufacturing Organization (CDMO) based in Shanghai, has...

Company Deals

LePure Bio Secures Hundreds of Millions in Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions”...

Company Deals

Shenzhen Keyto Fluid Control Secures Series C Funding for Expansion

Fineline Cube Jan 13, 2023

Shenzhen Keyto Fluid Control Co., Ltd, a China-based manufacturer of precision fluid control components, has...

Posts pagination

1 … 521 522 523 … 614

Recent updates

  • Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency
  • Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture
  • HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing
  • Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30
  • Knature Biopharm Files Hong Kong IPO Backed by NAD+ Mitochondrial Platform
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Visen Pharma Secures NMPA Approval for Skytrofa in Pediatric Growth Hormone Deficiency

Company Deals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Company Deals

HanchorBio Partners with WuXi Biologics on Next‑Gen Fusion Protein Manufacturing

Company Drug

Ascletis Doses First Patient in US Phase II Diabetes Study for Oral GLP‑1 ASC30

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.